Monoclonal Gammopathy of Undetermined Significance (MGUS) Overview

Save information for later
Sign Up

Learn About Monoclonal Gammopathy of Undetermined Significance (MGUS)

What is the definition of Monoclonal Gammopathy of Undetermined Significance (MGUS)?
Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop.
What are the alternative names for Monoclonal Gammopathy of Undetermined Significance (MGUS)?
  • Monoclonal gammopathy of undetermined significance
  • MGUS
Who are the top Monoclonal Gammopathy of Undetermined Significance (MGUS) Local Doctors?
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Anwar Khurshid
Hematology Oncology | Oncology
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Anwar Khurshid
Hematology Oncology | Oncology

Texas Oncology PA

515 W Mayfield Rd, Suite 101, 
Arlington, TX 
 (9.0 mi)
817-664-4400
Languages Spoken:
English, Dutch, French, German, Mandarin, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Anwar Khurshid is a Hematologist Oncology specialist and an Oncologist in Arlington, Texas. Dr. Khurshid and is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Breast Cancer, Drug-Induced Thrombocytopenia, Paget Disease of the Breast, and Thrombocytopenia. Dr. Khurshid is currently accepting new patients.

Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Chandini Sajja
Internal Medicine
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Chandini Sajja
Internal Medicine

Huguley Medical Associates, Inc

501 E Broad St, 
Mansfield, TX 
 (0.2 mi)
682-341-7200
Languages Spoken:
English
Accepting New Patients

Chandini Sajja is an Internal Medicine provider in Mansfield, Texas. Dr. Sajja and is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Factor 10 Deficiency, High Potassium Level, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Sajja is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Bilal K. Salame
Hematology Oncology | Hematology | Oncology
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Bilal K. Salame
Hematology Oncology | Hematology | Oncology

Texas Oncology PA

252 Matlock Rd, Suite 140, 
Mansfield, TX 
 (0.6 mi)
817-435-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bilal Salame is a Hematologist Oncology specialist and a Hematologist in Mansfield, Texas. Dr. Salame and is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Deep Vein Thrombosis, Anemia, Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia. Dr. Salame is currently accepting new patients.

View All Doctors
What are the latest Monoclonal Gammopathy of Undetermined Significance (MGUS) Clinical Trials?
CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study
CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study
Enrollment Status: Recruiting
Publish Date: February 13, 2025
Intervention Type: Other

Summary: The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active Myeloma (TACTAM)
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active Myeloma (TACTAM)
Who is this study for: Patients with Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Biological
Study Drug: TAA-specific CTLs
Study Phase: Phase 1

Summary: This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center